Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Capital Expenditures: 2014-2025

Historic Capital Expenditures for Viridian Therapeutics, Inc.\DE (VRDN) over the last 10 years, with Sep 2025 value amounting to $127,000.

  • Viridian Therapeutics, Inc.\DE's Capital Expenditures fell 56.66% to $127,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $369,000, marking a year-over-year decrease of 56.54%. This contributed to the annual value of $511,000 for FY2024, which is 43.10% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Capital Expenditures stood at $127,000, which was up 202.38% from $42,000 recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Capital Expenditures high stood at $404,000 for Q3 2023, and its period low was $15,000 during Q1 2021.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Capital Expenditures averaged around $166,400, with its median value being $120,500 (2024).
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Capital Expenditures spiked by 1,093.33% in 2022 and then crashed by 79.22% in 2023.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Capital Expenditures stood at $84,000 in 2021, then spiked by 175.00% to $231,000 in 2022, then slumped by 79.22% to $48,000 in 2023, then soared by 137.50% to $114,000 in 2024, then plummeted by 56.66% to $127,000 in 2025.
  • Its Capital Expenditures was $127,000 in Q3 2025, compared to $42,000 in Q2 2025 and $86,000 in Q1 2025.